G · Genpact LTD

Track G — free

$33.65 +0.20 (+0.60%) At close · Oct 7

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$5.67B

168.03M

Volume · Oct 7 1.71M Avg daily vol (3M) 2.19M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 7, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$5.25B

Trailing 12 months

Net income (TTM)

$582.65M

Trailing 12 months

Revenue growth YoY

+7.1%

Year over year

Operating margin

14.8%

Trailing 12 months

P / E (TTM)

9.9

Trailing earnings · reciprocal yield 10.1%

FCF yield

10.1%

TTM · current market cap

Return on invested capital

18.2%

Trailing 12 months

Net cash

−$662.87M

Latest balance sheet

Dividend yield

1.7%

Trailing 12 months

Shares change YoY

-3.7%

Year over year · fewer shares

Price change (1Y)

-18.6%

Trailing year

Short interest

6.5%

Latest settlement · 5.6 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. Genpact reported Q2 revenue up 7.1% and raised its full-year Advanced Technology Solutions growth outlook to at least 25% (from prior mid-teens) and adjusted diluted EPS growth to at least 12%, while announcing it is intentionally exiting certain non-strategic work that will weigh about two points on 2026 revenue growth.

Bullish

+ Raised full-year ATS revenue growth outlook to at least 25% from prior mid-teens.
+ ATS revenue grew 24.1% YoY and accounted for nearly 40% of record quarterly bookings.
+ Adjusted diluted EPS up 13.6% to $1.00, faster than revenue growth.
+ Tracking to over $1 billion in agentic TCV in 2026, five times 2025, with more than half from new clients.

Bearish

− Core Business Services revenue growth slowed to 1.9% in Q2.
− Q2 cash from operations of $72 million was well below the $177 million generated in Q2 2025.
− Q3 core business services expected to be flat to slightly down, weighed by about three points from the strategic transition.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol High

Market backdrop VIX 15.1 · calm Equity put/call 0.63

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −7%

below

Price vs 50-day avg −4%

below

RSI (14) 46

neutral

MACD trend Negative

52-week position 29%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −4%

trailing

6-month return −8%

trailing

YTD return −28%

this year

Relative strength −19%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $35 › 200d $36 — 200d above 50d

Institutional flow Accumulating

9 of 481 funds reported for Sep 30 · net +174.3K sh shares · +1 new

Insider flow Distributing

Net -$2.3M over 90 days · 100% sells

Short interest Falling

6.48% of float · ▼ -4.7% MoM · 5.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

481 holders — mid 3-yr range

Squeeze score 52

elevated · 0–100

Fundamentals

Excellent

Revenue growth +7%

Y/Y

Gross margin 80%

expanding

EPS growth +10%

Y/Y

Free cash flow $734.7M

Valuation P/E 10

below peers

Buyback $244.1M

remaining

Balance sheet $688.5M

net debt

Quant / Vol

risk profile

High

Volatility 40%

annualized · 1-yr

Max drawdown −43%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 7 of last 7

Latest guidance · from the 8-K filed Aug 6, 2026

Net revenue growth · full year 2026 Initiated at least 7%

Adjusted income from operations margin · full year 2026 Non-GAAP Initiated 17.7%

Adjusted diluted earnings per share growth · full year 2026 Non-GAAP Initiated at least 12%

Prior guidance period ended · from the 8-K filed Aug 6, 2026

Net revenues · third quarter of 2026 $1.37B – $1.38B

Adjusted income from operations margin · third quarter of 2026 17.8%

Adjusted diluted earnings per share · third quarter of 2026 $1.04 – $1.05

Guided vs delivered · last 7 settled

Total revenue third quarter of 2024

guided $1.18B – $1.19B

guided $1.18B – $1.19B $1.21B Beat +2.4%

Total revenue full year 2024

guided $4.66B – $4.7B

guided $4.66B – $4.7B $4.77B Beat +1.9%

Total revenue second quarter of 2024

guided $1.14B – $1.15B

guided $1.14B – $1.15B $1.18B Beat +2.7%

Total revenue first quarter of 2024

guided $1.11B – $1.11B

guided $1.11B – $1.11B $1.13B Beat +1.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 5 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−7% Bearish

Price vs 50-day avg

−4% Neutral

RSI (14)

46 Neutral

MACD trend

Negative Bearish

52-week position

29% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $35 › 200d $36 — 200d above 50d

Institutional flow Accumulating

9 of 481 funds reported for Sep 30 · net +174.3K sh shares · +1 new

Insider flow Distributing

Net -$2.3M over 90 days · 100% sells

Short interest Falling

6.48% of float · ▼ -4.7% MoM · 5.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

481 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $28 Now $34 · 29% Range high $49

vs 200-day avg -7% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
AOI - Consumer and Healthcare non-GAAP	$72.53M	three months ended June 30, 2026 filing	—
AOI - Financial Services non-GAAP	$67.84M	three months ended June 30, 2026 filing	—
AOI - High Tech and Manufacturing non-GAAP	$89.68M	three months ended June 30, 2026 filing	—
average headcount	143,100	the second quarter of 2026 filing	—
effective tax rate	23.7%	the second quarter of 2026 filing	—
gross margin	36.5%	the second quarter of 2026 filing	—
revenue growth on a constant currency basis non-GAAP	6.9%	the second quarter of 2026 compared to the second quarter of 202 filing	—
weighted average rate of interest on debt	5.4%	the second quarter of 2026 filing	—
Adjusted diluted EPS non-GAAP	$1.98	Six months ended June 30, 2026	—
Adjusted income from operations non-GAAP	$457.24M	Six months ended June 30, 2026	—
Adjusted income from operations margin non-GAAP	17.3%	Six months ended June 30, 2026	—
Adjusted net income non-GAAP	$339.96M	Six months ended June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Information Technology Services — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
G Genpact LTD this stock	$5.67B	-28.1%	+6.9%	10.0	6.5%
IBM International Business Machines Corp	$207.75B	-25.6%	+7.6%	19.5	2.4%
ACN Accenture plc	$116.59B	-26.7%	+7.4%	14.0	3.7%
INFY Infosys Ltd	$42.73B	-40.8%	—	—	3.1%
CTSH Cognizant Technology Solutions Corp	$27.26B	-31.2%	+7.0%	12.5	7.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

481

% held: 107.1%
Reported: 9 of 481
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

197

View

Short & Settlement

Short Interest Falling

Shares short

10.9M

Days to cover: 5.6d
Change: -540.0K sh

View

Short Volume

Short vol %

64%

As of: Oct 7, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $264
As of: Sep 2, 2026

View

Off-Exchange

Off-exchange %

38.1%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$2.3M

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Congressional Trades Sell

Member

Donna Shalala

Amount: $1.0K–$15.0K
Traded: Jun 24, 2019

View

Financials

Revenue (FY)

$5.1B

Net income (FY): $552.5M
EPS diluted: $3.13

View

Buybacks

Authorized

$2.8B

Remaining: $244.1M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K/A

Filed: Sep 18, 2026
This year: 10

View

Proposed Sales

Value

$367.9K

Shares: 10.0K
Filed: Sep 14, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
G	+3.4%	-3.5%	-8.1%	+3.4%	-28.1%
SPY	+1.9%	+1.9%	+10.8%	+1.9%	+14.0%
vs SPY	+1.5%	-5.4%	-18.9%	+1.5%	-42.1%

Capital returns

Latest dividend

$0.188 / share · ex Sep 10, 2026

Raised 10.6%

Paid (TTM)

$0.734 / share · 4 payouts

Dividend yield (TTM, derived)

2.18%

Buyback program · as of Jun 30, 2026

Authorized

$2.75B

Spent (derived)

$2.51B

Remaining

$244.14M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1398659 CUSIP G3922B107 13F (30d) 14 filings 14 filers Visit website Investor relations

G · Genpact LTD

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns